#PeproMene_Bio
LightNews LightNews
newsen.bsky.social
PeproMene Bio to Present PMB-CT01 Data at EHA 2026 Conference#USA#Irvine#PeproMene_Bio#PMB-CT01#EHA_2026
PeproMene Bio to Present PMB-CT01 Data at EHA 2026 Conference
PeproMene Bio, Inc. will showcase promising results for PMB-CT01 in treating B-cell lymphomas at the EHA 2026 conference, emphasizing safety and efficacy.
third-news.com
May 29, 2026 at 5:08 AM
newsen.bsky.social
Promising Safety and Efficacy of BAFF-R CAR T-Cell Therapy in B-Cell Lymphomas to Be Presented at EHA 2026#USA#Irvine#PeproMene_Bio#PMB-CT01#B-cell_Lymphomas
Promising Safety and Efficacy of BAFF-R CAR T-Cell Therapy in B-Cell Lymphomas to Be Presented at EHA 2026
PeproMene Bio will showcase pivotal Phase 1 results on PMB-CT01, a novel CAR T-cell therapy for B-cell lymphomas, at the EHA 2026 Congress.
third-news.com
May 28, 2026 at 11:19 AM
newsen.bsky.social
PeproMene Bio to Present Promising Clinical Data on PMB-CT01 at EHA 2026#USA#Irvine#PeproMene_Bio#PMB-CT01#EHA_2026
PeproMene Bio to Present Promising Clinical Data on PMB-CT01 at EHA 2026
PeproMene Bio, Inc. is set to present data from its Phase 1 study of PMB-CT01, showing a favorable safety profile and durable responses in B-cell lymphomas at the EHA 2026 conference.
third-news.com
May 29, 2026 at 1:28 PM
newsen.bsky.social
PeproMene Bio Set to Present Data on Innovative CAR-T Therapy for B-cell Lymphomas at EHA 2026#USA#Irvine#CAR-T_therapy#PeproMene_Bio#PMB-CT01
PeproMene Bio Set to Present Data on Innovative CAR-T Therapy for B-cell Lymphomas at EHA 2026
PeproMene Bio announces key findings on PMB-CT01, a CAR-T therapy showing promising responses in B-cell lymphomas at EHA 2026.
third-news.com
May 29, 2026 at 12:29 PM
newsen.bsky.social
PeproMene Bio Presents Promising Data on CAR T-Cell Therapy for B-Cell Lymphomas at EHA 2026#USA#Irvine#PeproMene_Bio#PMB-CT01#B-cell_Lymphomas
PeproMene Bio Presents Promising Data on CAR T-Cell Therapy for B-Cell Lymphomas at EHA 2026
PeproMene Bio, Inc. shares promising clinical results for their PMB-CT01 therapy aimed at treating B-cell lymphomas, as seen at EHA 2026.
third-news.com
May 28, 2026 at 11:26 AM
newsen.bsky.social
PeproMene Bio Makes History with Promising Phase 1 Trial Results for B-cell Lymphomas#USA#Irvine#B-cell_Lymphoma#PeproMene_Bio#PMB-CT01
PeproMene Bio Makes History with Promising Phase 1 Trial Results for B-cell Lymphomas
PeproMene Bio has published groundbreaking Phase 1 trial results in The Lancet, showcasing durable responses in tough B-cell lymphoma cases.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
PeproMene Bio's Breakthrough Cancer Therapy Shows Promising Phase 1 Trial Results Published in The Lancet#USA#Irvine#CAR_T-cell_Therapy#B-cell_Lymphoma#PeproMene_Bio
PeproMene Bio's Breakthrough Cancer Therapy Shows Promising Phase 1 Trial Results Published in The Lancet
PeproMene Bio recently published significant results in The Lancet, revealing their innovative CAR T-cell therapy's efficacy for treating B-cell lymphomas, even after prior treatment failures.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
Breakthrough Clinical Trial Results for B-cell Lymphomas Published in The Lancet by PeproMene Bio#USA#Irvine#PeproMene_Bio#PMB-CT01#BAFF-R
Breakthrough Clinical Trial Results for B-cell Lymphomas Published in The Lancet by PeproMene Bio
PeproMene Bio announces exciting results from a Phase 1 clinical trial, highlighting durable responses in treating relapsed B-cell lymphomas. Featured in The Lancet.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
PeproMene Bio's Groundbreaking Publication in The Lancet Showcases Promising CAR T-Cell Therapy for B-Cell Lymphomas#USA#Irvine#CAR_T-cell_Therapy#B-cell_Lymphoma#PeproMene_Bio
PeproMene Bio's Groundbreaking Publication in The Lancet Showcases Promising CAR T-Cell Therapy for B-Cell Lymphomas
PeproMene Bio has announced the publication of significant Phase 1 trial results in The Lancet demonstrating effective CAR T-cell therapy for B-cell lymphomas.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
Groundbreaking Phase 1 Study Results Published in The Lancet on PMB-CT01 for Treating Advanced B-Cell Lymphomas#USA#Irvine#CAR-T_therapy#PeproMene_Bio#PMB-CT01
Groundbreaking Phase 1 Study Results Published in The Lancet on PMB-CT01 for Treating Advanced B-Cell Lymphomas
PeproMene Bio has released groundbreaking findings in The Lancet showcasing the potential of PMB-CT01, a novel CAR-T cell therapy, for treating resistant B-cell lymphomas in patients.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
PeproMene Bio to Present Groundbreaking CAR T Therapy Data at ASH 2025#USA#Irvine#PeproMene_Bio#PMB-CT01#ASH_2025
PeproMene Bio to Present Groundbreaking CAR T Therapy Data at ASH 2025
PeproMene Bio will showcase its innovative CAR T therapy PMB-CT01 for B-cell malignancies at the upcoming ASH 2025 conference, highlighting its promising results.
third-news.com
November 21, 2025 at 12:50 PM
newsen.bsky.social
PeproMene Bio's PMB-CT01 Selected for Presentations at ASH 2025 Annual Meeting#USA#Irvine#PeproMene_Bio#PMB-CT01#BAFFR-CAR_T
PeproMene Bio's PMB-CT01 Selected for Presentations at ASH 2025 Annual Meeting
PeproMene Bio announces that two abstracts on PMB-CT01 have been accepted for oral presentations at ASH 2025, showcasing its promising results in treating B-cell malignancies.
third-news.com
November 20, 2025 at 9:39 PM
newsen.bsky.social
Recent Data from PeproMene Bio's Clinical Trial Selected for Two Presentations at ASH 2025#USA#Irvine#PeproMene_Bio#PMB-CT01#ASH_2025
Recent Data from PeproMene Bio's Clinical Trial Selected for Two Presentations at ASH 2025
PeproMene Bio's PMB-CT01 study data has been accepted for two significant presentations at the upcoming ASH 2025 Annual Meeting, highlighting promising results.
third-news.com
November 20, 2025 at 9:26 PM
newsen.bsky.social
PeproMene Bio Announces Exciting Data Presentations for PMB-CT01 at 2025 ASH Annual Meeting#USA#Irvine#PeproMene_Bio#PMB-CT01#BAFFR-CAR_T
PeproMene Bio Announces Exciting Data Presentations for PMB-CT01 at 2025 ASH Annual Meeting
PeproMene Bio's PMB-CT01 BAFFR-CAR T therapy shows promising results for B-cell malignancies, poised for two oral presentations at ASH 2025.
third-news.com
November 20, 2025 at 5:13 PM
newsen.bsky.social
PeproMene Bio's PMB-CT01 Selected for Key Presentations at ASH 2025#USA#Irvine#B-ALL#PeproMene_Bio#B-NHL
PeproMene Bio's PMB-CT01 Selected for Key Presentations at ASH 2025
PeproMene Bio reveals promising results for PMB-CT01 in treating relapsed B-cell malignancies at the upcoming ASH 2025 Annual Meeting, highlighting safety and efficacy.
third-news.com
November 20, 2025 at 5:12 PM
newsen.bsky.social
PeproMene Bio Announces Full Remission in First Patient with Follicular Lymphoma Treated with CAR-T Therapy#USA#Irvine#CAR-T_therapy#Follicular_Lymphoma#PeproMene_Bio
PeproMene Bio Announces Full Remission in First Patient with Follicular Lymphoma Treated with CAR-T Therapy
PeproMene Bio has reported that the first patient with follicular lymphoma treated with BAFF-R CAR-T therapy achieved full remission, showcasing promising results in cancer treatment.
third-news.com
May 23, 2025 at 3:28 PM
newsen.bsky.social
Promising Breakthrough in Treating Indolent Follicular Lymphoma with CAR-T Therapy#USA#California#CAR-T_therapy#Follicular_Lymphoma#PeproMene_Bio
Promising Breakthrough in Treating Indolent Follicular Lymphoma with CAR-T Therapy
The first patient treated with BAFF-R directed CAR-T cells by PeproMene Bio achieves complete remission. A significant advancement in lymphoma treatment.
third-news.com
May 23, 2025 at 3:19 PM
newsen.bsky.social
First Patient with Follicular Lymphoma Achieves Complete Response with BAFF-R Targeting CAR-T Cells#USA#Irvine#Follicular_Lymphoma#PeproMene_Bio#BAFF-R_CAR-T
First Patient with Follicular Lymphoma Achieves Complete Response with BAFF-R Targeting CAR-T Cells
PeproMene Bio announces that the first patient with follicular lymphoma treated with BAFF-R CAR-T cells has achieved complete remission, marking a significant advancement in cancer therapy.
third-news.com
May 23, 2025 at 3:18 PM
newsen.bsky.social
Breakthrough in Follicular Lymphoma Treatment with BAFF-R Targeting CAR-T Cells#USA#Irvine#Follicular_Lymphoma#PeproMene_Bio#BAFF-R_CAR-T
Breakthrough in Follicular Lymphoma Treatment with BAFF-R Targeting CAR-T Cells
PeproMene Bio announces a significant milestone in cancer treatment as the first patient with follicular lymphoma achieves complete remission using BAFF-R targeting CAR-T cells.
third-news.com
May 20, 2025 at 3:28 PM
newsen.bsky.social
Revolutionary CAR-T Cell Therapy Shows Promising Results in Follicular Lymphoma Treatment#USA#Irvine#Follicular_Lymphoma#PeproMene_Bio#BAFF-R_CAR-T
Revolutionary CAR-T Cell Therapy Shows Promising Results in Follicular Lymphoma Treatment
PeproMene Bio announces a groundbreaking achievement in treating follicular lymphoma with CAR-T cells, marking hope for patients with this challenging disease.
third-news.com
May 20, 2025 at 3:27 PM
newsen.bsky.social
PeproMene Bio and IFLI Announce $11 Million Investment for Innovative Lymphoma Treatment#USA#Irvine,_California#PeproMene_Bio#IFLI#PMB-CT01
PeproMene Bio and IFLI Announce $11 Million Investment for Innovative Lymphoma Treatment
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation have announced an $11 million investment to advance the PMB-CT01 treatment for relapsed or refractory follicular lymphoma.
third-news.com
December 19, 2024 at 10:48 PM
newsen.bsky.social
PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement#USA#Irvine#PeproMene_Bio#IFLI#PMB-CT01
PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement
PeproMene Bio, Inc. has secured an $11 million investment to advance PMB-CT01, a CAR T cell therapy targeted at relapsed/refractory follicular lymphoma, following encouraging initial results.
third-news.com
December 19, 2024 at 10:02 PM
newsen.bsky.social
PeproMene Bio and IFLI Invest $11 Million for Promising Lymphoma Therapy in Patients#United_States#Irvine#PeproMene_Bio#IFLI#PMB-CT01
PeproMene Bio and IFLI Invest $11 Million for Promising Lymphoma Therapy in Patients
PeproMene Bio announces an $11 million investment to enhance the development of PMB-CT01, a CAR T-cell therapy for lymphoma patients, following promising trial results.
third-news.com
December 19, 2024 at 9:52 PM
newsen.bsky.social
PeproMene Bio Secures $11M for Innovative CAR T Cell Therapy in Cancer Treatment#USA#CAR_T_Therapy#Follicular_Lymphoma#Irvine,_California#PeproMene_Bio
PeproMene Bio Secures $11M for Innovative CAR T Cell Therapy in Cancer Treatment
PeproMene Bio, in collaboration with IFLI, secures an $11 million investment to advance a groundbreaking CAR T cell therapy for follicular lymphoma in clinical trials.
third-news.com
December 19, 2024 at 3:12 PM
newsen.bsky.social
PeproMene Bio Secures $11M Investment to Enhance CAR T Cell Therapy for Lymphoma Patients#USA#Irvine#CAR_T_Therapy#Follicular_Lymphoma#PeproMene_Bio
PeproMene Bio Secures $11M Investment to Enhance CAR T Cell Therapy for Lymphoma Patients
In a significant boost for cancer therapy, PeproMene Bio has gained an $11 million investment to enhance its promising CAR T cell therapy for treating follicular lymphoma.
third-news.com
December 19, 2024 at 3:11 PM